SG3 Management’s Zevra Therapeutics ZVRA Stock Holding History

SG3 Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-37,500	Closed	-$327K	–	1418
2021 Q4	$327K	Buy	+37,500	New	+$335K	0.01%	730

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

RPCONE

Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return

SG3 Management's ZVRA Position: Q1 2022 in Review

SG3 Management sold out of Zevra Therapeutics (ZVRA) in Q1 2022, closing a stake of 37,500 shares — an estimated $327K sold.

SG3 Management first reported a position in ZVRA in Q4 2021 and held it in 1 quarter. The position peaked at $327K in Q4 2021. 83 funds tracked by Wall St. Rank hold ZVRA as of Q1 2022.

SG3 Management reported no remaining Zevra Therapeutics position as of Q1 2022 after selling out during the quarter.
SG3 Management sold 37,500 Zevra Therapeutics shares in Q1 2022, an estimated $327K.
SG3 Management first reported a position in Zevra Therapeutics in Q4 2021 and held it in 1 quarter.
SG3 Management's Zevra Therapeutics position peaked at $327K in Q4 2021.
83 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.